Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALINA: Palbociclib Safety in African American Women with HR+/HER2- Advanced Breast Cancer
NCT02692755Phase 3Completed
- Sponsor
- Georgetown University
- Start
- Sep 2016
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of palbociclib in Hormone-Receptor-Positive Breast Cancer, sponsored by Georgetown University. Primary endpoint: Number of Patients Who Complete Planned Oncologic Therapy Without the Development of a Hematological Event at 12 months. Started Sep 2016; status: completed.
02
Drugs
palbociclib
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT02692755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02692755.